Fujirebio Diagnostics, Inc. Snaps Up Offloaded Abbott Diagnostics Unit

SCRIP -- The Japanese firm Fujirebio is to pay ¥9.8 billion ($112.9 million) for Innogenetics, a Belgian diagnostics and biologics operation acquired by Abbott as part of the US firm's broader purchase of Solvay Pharmaceuticals earlier this year.